20:23 , May 22, 2019 |  BC Extra  |  Company News

In a rare M&A move, Amgen proposes to acquire partner Nuevolution

In what would be its first acquisition since 2015, Amgen offered on Wednesday to buy Copenhagen-based small molecule discovery company Nuevolution for about $167 million in cash. Amgen Inc. (NASDAQ:AMGN) has proposed to pay SEK32.50...
08:00 , Feb 29, 2016 |  BioCentury  |  Product Development

Oncolytic pipeline

Oncolytic pipeline At least 19 oncolytic viruses are in clinical development. For products in development for multiple indications, the status of the lead indication is shown. Many viruses are now being studied in combination with...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Company News

Catherex, Amgen deal

Amgen is acquiring Catherex for $10.5 million up front. Catherex shareholders are also eligible for regulatory and sales milestones related to Amgen’s Imlygic talimogene laherparepvec, plus royalties until the end of 2020. The oncolytic virus...
01:49 , Dec 22, 2015 |  BC Extra  |  Company News

Medigene rises on spin-off sale

Medigene AG (Xetra:MDG1) added EUR 1.07 (15%) to EUR 8.15 on Monday on news that Amgen Inc. (NASDAQ:AMGN) bought Medigene spinoff Catherex Inc. (Philadelphia, Pa.) for $10.5 million up front. Catherex shareholders are also eligible...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms IL-12-expressing oncolytic herpes virus to treat glioblastoma Mouse studies identified an oncolytic virus expressing IL-12 that could help treat glioblastoma. In...
08:00 , Jan 31, 2011 |  BioCentury  |  Strategy

Lysing what it sees

Since the approval of Dendreon Corp. 's Provenge finally validated the idea of cancer immunotherapy, one of the next big questions has been how this treatment modality would be incorporated into the portfolios of major...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

Catherex, Medigene deal

MediGene divested its oncolytic herpes simplex virus (HSV) program to Catherex in exchange for a 40% stake in the new company. The program includes NV1020 and G207 , which are in Phase I/II testing to...
07:00 , Apr 19, 2010 |  BioCentury  |  Finance

Regulatory milestones

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was off $0.09 to $54.87 last week after the company said the Japanese Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria...
00:58 , Apr 14, 2010 |  BC Extra  |  Company News

MediGene divests oncolytic HSV program

MediGene AG (Xetra:MDG) divested its oncolytic herpes simplex virus (HSV) program to Catherex Inc. (Philadelphia, Pa.) in exchange for a 40% stake in the new company. The program includes NV1020 and G207, which are in...